Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Steve Kelsey, M.D.

GlobeNewsWire • Jun 22, 2026

Revolution Medicines: Strong Data, Big Market (Rating Upgrade)

Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib's Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity.

Seeking Alpha • Jun 13, 2026

Can Revolution Medicines Be a Game-Changer Stock?

Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs.

The Motley Fool • Jun 11, 2026

Tango Skyrockets 47% On Eye-Popping Pancreatic Cancer Results

Tango Therapeutics stock skyrocketed Monday after the biotech company added to the Revolution Medicines's results in pancreatic cancer.

Investors Business Daily • Jun 8, 2026

Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.

Revolution Medicines' leading candidates posted strong phase 3 clinical trial results. The medicine's peak sales potential looks enormous.

The Motley Fool • Jun 5, 2026

Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

Seeking Alpha • Jun 1, 2026

RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study

Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.

Zacks Investment Research • Jun 1, 2026

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients ​live 15% longer than BeOne Medicines' Tevimbra immunotherapy.

Reuters • Jun 1, 2026

Revolution's pancreatic cancer drug doubles survival, boosts quality of life

Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could resume ​activities they had previously abandoned, setting a new benchmark for this deadly cancer, researchers reported on Sunday.

Reuters • May 31, 2026